Fig 1: Plasma concentration of high-mobility group box 1 protein ((A): HMGB1), soluble receptor for advanced glycation end-products ((B): sRAGE), reactive oxygen/nitrogen species ((C): ROS/RNS), apolipoprotein D ((D): ApoD), and nuclear factor erythroid 2-related factor 2 ((E): NRF2), according to the control, Alzheimer’s disease (AD), and alcohol use disorder (AUD) subgroups with (+) and without (−) cognitive impairment (CI). Representative western blots of the sRAGE protein have been included in panel (F). Data were analyzed by Games–Howell post-hoc test or Student’s t test (single effect in (B,E), when appropriate. Bars represent means ± standard deviations. Symbols: */** p < 0.05/0.01 versus control group; # p < 0.05 versus respective AD-CI and AD+CI subgroups.
Fig 2: Plasma concentration of high-mobility group box 1 protein ((A): HMGB1), soluble receptor for advanced glycation end-products ((B): sRAGE), reactive oxygen/nitrogen species ((C): ROS/RNS), apolipoprotein D ((D): ApoD), and nuclear factor erythroid 2-related factor 2 ((E): NRF2), according to the control, Alzheimer’s disease (AD), and alcohol use disorder (AUD) groups. Representative western blots of the sRAGE protein have been included in panel (F). Data were analyzed by Games–Howell post-hoc test or Student’s t test (single effect in (B)), when appropriate. Bars represent means ± standard deviations. Symbols: */**/*** p < 0.05/0.01/0.001 versus control group; #/### p < 0.05/0.001 versus AD group.
Supplier Page from CUSABIO Technology LLC for Human Nuclear factor erythroid 2-related factor 2(NFE2L2) ELISA Kit